A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Serial analysis of FDG PET scans for early response evaluation in malignant pleural mesothelioma
Letizia Gianoncelli,Elena Lorenzi,Giovanni Luca Ceresoli,Ros Francis,Jan Boucek,Laura Giordano,Marcello Rodari,Paolo Andrea Zucali,Armando Santoro,Arturo Chiti +9 more
Journal ArticleDOI
Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Armando Santoro,Rita Mazza,Alessandro Pulsoni,Alessandro Re,Maurizio Bonfichi,Vittorio Ruggero Zilioli,Flavia Salvi,Antonella Anastasia,Stefano Luminari,Manuel Gotti,Annalisa Peli,Anna Marina Liberati,Nicola Di Renzo,Luca Castagna,Laura Giordano,Carmelo Carlo-Stella +15 more
TL;DR: This phase II study demonstrates that BeGEV is a highly effective salvage regimen able to induce a remarkable proportion of complete remission prior to ASCT in relapsed/refractory HL patients, and provides a strong rationale for further development of the Be GEV regimen.
Journal ArticleDOI
Treatment of malignant pleural mesothelioma: current status and future directions
Paolo Andrea Zucali,Rita De Sanctis,Fabio De Vincenzo,Matteo Simonelli,Elena Lorenzi,Matteo Perrino,Armando Santoro +6 more
TL;DR: Improvements in surgical and radiotherapy techniques, in tumor assessment and staging and in the knowledge of the major molecular pathways involved in MPM are needed to increase the survival of these patients.
Minidose W arfarin P rophylaxis f or C atheter-Associa ted Thrombosis i n C ancer P atients: C an I t B e S afely A ssociated With F luorouracil-Bas ed C hemotherapy?
Giovanna Masci,Massimo Magagnoli,Paolo Andrea Zucali,L. Castagna,Carlo Carnaghi,Barbara Sarina,Vittorio Pedicini,Monica Fallini,Armando Santoro +8 more
TL;DR: Clinicians should be aware of this interaction and should regularly monitor the prothrombin time in patients receiving warfarin and FU-based regimens, especially those treated with FOLFOX regimen.
Journal ArticleDOI
A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients
Giulia Maggioni,Erica Travaglino,Ana Alfonso Pierola,Jennifer Kaivers,Montserrat Arnan,Manja Meggendorfer,Laura Giordano,Matteo Bersanelli,Cristina Astrid Tentori,Marta Ubezio,Lucio Morabito,Alessia Campagna,Emanuele Angelucci,Massimo Bernardi,Lorenza Borin,Maria Teresa Voso,Francesco Passamonti,Armando Santoro,Valeria Santini,Guillermo Sanz,Torsten Haferlach,Ulrich Germing,María Díez-Campelo,Matteo G. Della Porta +23 more
TL;DR: It is suggested that in MDS patients, sex may capture prognostic information on the detrimental interactions between anemia and cardiac comorbidity and the independent prognostic effect of sex was confirmed in two independent populations.